Efficacy and safety of rituximab biosimilars or reference product as first-line treatment in patients with low-tumour-burden follicular lymphoma: A systematic review and meta-analysis.
Liu YangZhiwei ZhengNa LiBin ZhengMaobai LiuHongfu CaiPublished in: Journal of clinical pharmacy and therapeutics (2022)
Our study concluded that the efficacy and safety of rituximab biosimilars in the treatment of LTB-FL are highly similar to those of the original drug.